Stephen Medlin

Founding Director and Endowed Chair for Stem Cell Transplant and Immunotherapy, Inova, Fairfax, Virginia

[Vincent Rajkumar @VincentRK]

Just out! New IMS/ IMWG Definition of High Risk Myeloma.
@JCO_ASCO #IMWG25

@Myeloma_Society @IMFmyeloma @NikhilMunshiMD @mvmateos @SagarLonialMD @szusmani @NoopurRajeMD

[Tim Fenske @timfenske]

@RenoHemonc @mtmdphd @beatalleukemia @Froedtert @ldandersonjr @scmedlin @MCWCancerCenter There is an online calculator

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

CH and blood counts predicts MN risk - @beatalleukemia
Saint Kate Hotel, Milwaukee, WI @Froedtert

[Vincent Rajkumar @VincentRK]

Please watch this if you are a doctor practicing in the US.

Things are far worse now with the ABIM. #MedTwitter #EndMOC

[chadi nabhan MD, MBA, FACP @chadinabhan]

This 2016 video by Dr. Teirstein Pres of @InfoNbpas would B the BEST 15 mins of UR time today.

Just pls watch. Paul will appear on #HealthcareUnfiltered soon to discuss more & provide a path forward. @AaronGoodman33 @VincentRK @doctorwes CC @MorieGertz

https://t.co/D5lFZaTdjO

[Vincent Rajkumar @VincentRK]

On ABIM MOC. Please read!!!

To maintain the trust of patients we need to test the testers who test doctors

@AaronGoodman33 @doctorwes @chadinabhan @DavidSteensma We must create a Board Exam to ensure that ABIM leaders are qualified Testers. Goal is to improve patient care.
1/

[Vincent Rajkumar @VincentRK]

This is sarcasm. In case you miss it. Don’t take it seriously.

😀

[Vincent Rajkumar @VincentRK]

ABIM must wake up to the realization that doctors carry a smart phone computer with them. We work in teams. We have colleagues who we can consult for rare disorders and when doubts arise

End MOC. It’s useless.
CME, maintenance of licensure & credentialing is enough.

[Stephen Medlin @scmedlin]

@mtmdphd @RahulBanerjeeMD So many questions come to mind
Is this of utility to follow in CAR..and what about changes in allo transplant patients …any interaction with the T cell subsets activity and changes in microbiome

Very interesting

[Stephen Medlin @scmedlin]

@mtmdphd Ordered a copy! 30 dollars and ships in 6 weeks on Amazon prime

A Physician's Journey: The Memoir of Robert A. Kyle, M.D. https://t.co/v25nOeVcPC
@VincentRK

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Whole-genome sequencing [WGS] of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides [Aug 2, 2012] Egan et al. @BloodJournal https://t.co/Jlmpr88dM4 #mmsm #cagenome

[Vincent Rajkumar @VincentRK]

I want to hear from @ASH_hematology and @ASCO on what concrete things have been accomplished since your letters and surveys on ABIM MOC?

@AaronGoodman33 @chadinabhan #MedTwitter

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

250 citations! --> Assoc of Clinical Factors & Recent Anti-Cancer Therapy w/ COVID-19 Severity among Patients with Cancer: Report from COVID-19 & Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology https://t.co/WH5PPJySj6 #CCC19 #COVID19nCancer

[Stephen Medlin @scmedlin]

@mtmdphd @jwsenefeld @DrJPHenderson @DrMJoyner @NEJM @COVID19nCCC @DrDimpyShah Really appreciate this insightful comment

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Convalescent Plasma for Covid-19–Induced ARDS [Jan 25, 2024] @jwsenefeld @DrJPHenderson @DrMJoyner @NEJM Letter DOI: 10.1056/NEJMc2313675 #COVID19CP #COVID19

[Nico Gagelmann @NicoGagelmann]

🎉Finally out🎉

Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma

The balance between improved efficacy, increased severe toxicity and resource utilization

Open access

⁦@AnnaSureda5⁩ #lymsm https://t.co/5b5NYGjO9d

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Editorial @FDAOncology @NEJM #mmsm
✅22 cases out of 27,000, 14 with data
✅T-cell lymphoma,T-cell large granular lymphocytosis,peripheral T-cell lymphoma,cutaneous T-cell lymphoma
🛑3 cases with genetic info,CAR transgene detected in malignant clone
➡️https://t.co/6IR5Kg7nhH

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Nice pre-clinical study shows bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth better than just targeting BCMA by enhancing macrophage phagocytic clearance of myeloma cells: https://t.co/0NgJMSPR68.